000 | 01374na a2200229 4500 | ||
---|---|---|---|
003 | H12O | ||
005 | 20180417105937.0 | ||
008 | 130622s2011 xxx||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_aGonzález Tomé, María Isabel _91354 _ePediatría |
||
245 | 0 | 0 |
_aHIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations _h[artículo] |
260 |
_bJournal of Adolescent Health, _c2011 |
||
300 | _a48(1):100-102. | ||
500 | _aFormato Vancouver: Nso Roca AP, Larru B, Bellón JM, Mellado MJ, Ramos JT, González MI, et al. HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations. J Adolesc Health. 2011;48(1):100-2. | ||
501 | _aPMID: 21185531 | ||
504 | _aContiene 10 referencias | ||
520 | _aThe use of atazanavir (ATV) in adolescents infected with human immunodeficiency virus was analyzed in this study. ATV morning plasma concentrations were determined during regular visits to the outpatient department. Results showed that bilirubin levels were higher among patients with higher ATV plasma concentrations (p = .018). Monitoring plasma levels of ATV could avoid toxicity in these patients. | ||
710 |
_9446 _aServicio de Pediatría-Neonatología |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/5/pc5557.pdf _ySolicitar documento |
||
942 |
_n0 _2ddc _cART |
||
999 |
_c5557 _d5557 |